SCHEMBL27492

SCHEMBL27492

c1ccc(CC2CCCCN2Cc2ccccc2)cc1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ammonia Solution, Strong SCHEMBL7288994 0.98
SCHEMBL11470279 0.98
SCHEMBL2997593 0.95
SCHEMBL5530480 0.95
Ammonia Solution, Strong SCHEMBL29243589 0.93
SCHEMBL6695674 0.91 OPRD1 (0.47)
SCHEMBL7244706 0.91 SPHK2 (0.49)
SCHEMBL11480291 0.91 ALDH1A1 (0.54)
SCHEMBL28627062 0.88
SCHEMBL6853109 0.87 CCR3 (0.53)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1657 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11040053-B2 Compositions and methods for activating “stimulator of interferon gene”13 dependent signalling CHINOOK THERAPEUTICS, INC. (US) 2021-06-22 US claimed
US-20200179431-A1 COMPOSITIONS AND METHODS FOR ACTIVATING \"STIMULATOR OF INTERFERON GENE\" - DEPENDENT SIGNALLING Aduro Biotech, Inc. (US) 2020-06-11 US claimed
US-10449211-B2 Compositions and methods for activating “stimulator of interferon gene”—dependent signalling Aduro Biotech, Inc. (US) 2019-10-22 US claimed
US-20180064745-A1 COMPOSITIONS AND METHODS FOR ACTIVATING \"STIMULATOR OF INTERFERON GENE\" - DEPENDENT SIGNALLING Aduro Biotech, Inc. (US) 2018-03-08 US claimed
EP-3268035-A1 COMPOSITIONS AND METHODS FOR ACTIVATING \"STIMULATOR OF INTERFERON GENE\" -DEPENDENT SIGNALLING Aduro BioTech, Inc. (US) 2018-01-17 EP claimed
WO-2016145102-A1 COMPOSITIONS AND METHODS FOR ACTIVATING \"STIMULATOR OF INTERFERON GENE\" -DEPENDENT SIGNALLING Aduro Biotech, Inc. (US) 2016-09-15 WO claimed
US-20130150323-A1 USE OF ORAL HEPARIN PREPARATIONS TO TREAT URINARY TRACT DISEASES AND CONDITIONS Urigen Pharmaceuticals, Inc (US) 2013-06-13 US claimed
EP-2531202-A2 USE OF ORAL HEPARIN PREPARATIONS TO TREAT URINARY TRACT DISEASES AND CONDITIONS Parsons, Lowell C. (US) 2012-12-12 EP claimed
WO-2011097148-A2 USE OF ORAL HEPARIN PREPARATIONS TO TREAT URINARY TRACT DISEASES AND CONDITIONS PARSONS LOWELL C (US) 2011-08-11 WO claimed
EP-4007758-B1 BIS-[N-((5-CARBAMOYL)-1H-BENZO[D]IMIDAZOL-2-YL)-PYRAZOL-5-CARBOXAMIDE] DERIVATIVES AND RELATED COMPOUNDS AS STING (STIMULATOR OF INTERFERON GENES) AGONISTS FOR THE TREATMENT OF CANCER MERSANA THERAPEUTICS INC (US) 2026-05-13 EP disclosed
US-20260109665-A1 C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS TETRAPHASE PHARMACEUTICALS INC (US) 2026-04-23 US disclosed
US-20260083838-A1 Adjuvant Composition Comprising STING Agonists GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2026-03-26 US disclosed
US-20260083769-A1 2-Aminopropane-1,3-Diol-Capped Cationic Peptoids for Nucleic Acid Delivery MEDICI THERAPEUTICS, INC. 2026-03-26 US disclosed
US-20260055132-A1 TLR7 AGONISTS PRIMMUNE THERAPEUTICS INC (US) 2026-02-26 US disclosed
EP-0101199-A1 Beta-lactam compounds BEECHAM GROUP PLC (GB) 1984-02-22 EP disclosed
EP-0093564-A1 Beta-lactam antibiotics BEECHAM GROUP PLC (GB) 1983-11-09 EP disclosed
EP-0092986-A1 Penicillins, a process for their preparation and compositions containing them BEECHAM GROUP PLC (GB) 1983-11-02 EP disclosed
EP-0091755-A1 Penicillin derivatives, a process for their preparation and compositions containing them BEECHAM GROUP PLC (GB) 1983-10-19 EP disclosed
EP-0091302-A1 Beta-lactam derivatives BEECHAM GROUP PLC (GB) 1983-10-12 EP disclosed
EP-0090656-A1 Penicillins, a process for the preparation and compositions containing them BEECHAM GROUP PLC (GB) 1983-10-05 EP disclosed